C
Christopher M. Nutting
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 379
Citations - 16711
Christopher M. Nutting is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Radiation therapy & Head and neck cancer. The author has an hindex of 58, co-authored 366 publications receiving 14403 citations. Previous affiliations of Christopher M. Nutting include Institute of Cancer Research & University of Warwick.
Papers
More filters
Journal ArticleDOI
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Christopher M. Nutting,Christopher M. Nutting,James P Morden,Kevin J. Harrington,Kevin J. Harrington,Teresa Guerrero Urbano,Shreerang Bhide,Catharine H. Clark,Elizabeth Miles,Aisha Miah,Kate Newbold,Mary Anne Lagmay Tanay,Fawzi Adab,Sarah Jefferies,Christopher D Scrase,Beng K. Yap,Roger A'Hern,M. Sydenham,M. Emson,Emma Hall +19 more
TL;DR: Sparing the parotid glands with IMRT significantly reduces the incidence of xerostomia and leads to recovery of saliva secretion and improvements in associated quality of life, and thus strongly supports a role for IMRT in squamous-cell carcinoma of the head and neck.
Journal ArticleDOI
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose,Christopher M. Nutting,Barbara Jarzab,Rossella Elisei,Salvatore Siena,Lars Bastholt,Christelle De La Fouchardiere,Furio Pacini,Ralf Paschke,Young Kee Shong,Steven I. Sherman,Johannes W. A. Smit,John Chung,Christian Kappeler,Carol Peña,Istvan Molnar,Martin Schlumberger +16 more
TL;DR: It is suggested that sorafenib is a new treatment option for patients with progressive radioactive iodine-refractory differentiated thyroid cancer and progression-free survival significantly improved in all prespecified clinical and genetic biomarker subgroups, irrespective of mutation status.
Journal ArticleDOI
Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines
Vincent Grégoire,Kian K. Ang,Wilfried Budach,Cai Grau,Marc Hamoir,Johannes A. Langendijk,Anne W.M. Lee,Quynh-Thu Le,Quynh-Thu Le,Philippe Maingon,Christopher M. Nutting,Brian O'Sullivan,Sandro V. Porceddu,Benoît Lengelé +13 more
TL;DR: In this article, a task force comprising opinion leaders in the field of head and neck radiation oncology from European, Asian, Australia/New Zealand and North American clinical research organizations was formed to review and update the previously published guidelines on nodal level delineation.
Journal ArticleDOI
A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor
Jennifer C.C. Hu,Robert S. Coffin,Ceri J. Davis,Nicola J. Graham,Natasha Groves,Peter J. Guest,Kevin J. Harrington,Nicholas D. James,Colin Love,Iain A. McNeish,Louise C. Medley,Agnieszka Michael,Christopher M. Nutting,Hardev Pandha,Claire A. Shorrock,Julie Simpson,Jan Steiner,Neil Steven,Dennis Wright,R. Charles Coombes +19 more
TL;DR: Onco VEXGM-CSF is well tolerated and can be safely administered using the multidosing protocol described, and evidence of an antitumor effect was seen.
Journal ArticleDOI
Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer
Ujjal Mallick,Clive Harmer,Beng K. Yap,Jonathan Wadsley,Susan E. M. Clarke,Laura Moss,Alice Nicol,Penelope M. Clark,Kate Farnell,Ralph V McCready,James Smellie,J. A. Franklyn,Rhys John,Christopher M. Nutting,Kate Newbold,Catherine Lemon,Georgina Gerrard,Abdel Abdel-Hamid,John Hardman,Elena Macias,Tom Roques,Stephen Whitaker,Rengarajan Vijayan,Pablo Alvarez,Sandy Beare,Sharon Forsyth,Latha Kadalayil,Allan Hackshaw +27 more
TL;DR: Low-dose radioiodine plus thyrotropin alfa was as effective as high-doseRadioiodine, with a lower rate of adverse events, in a randomized noninferiority trial of patients with differentiated thyroid cancer.